PYROTECH THERAPEUTICS

Pyrotech is based on ground-breaking discoveries regarding ‘pyroptosis’, which is a type of cell death that controls infections by stimulating strong immune responses.

Launch date

2020

Employees

11-50 people

Market cap

Enterprise valuation

AUD956m (Public information from May 2024)

Beijing China (HQ)

https://www.pyrotech.com/

https://www.linkedin.com/company/pyrotech-therapeutics/

Date	Investors	Amount	Round
-	LSV Capital China Life Asset Management China Venture Capital Lotus Lake Capital	N/A	-
Jan 2021*	MSA Capital Lilly Asia Ventures Shanghai Ziyou Investment Management Zhongguancun Development Group BioTrack Capital Chang Development Qisheng Capital QingLan Fund Beijing Life Science Park Venture Capital	N/A	Seed
Jul 2023*	MSA Capital Lilly Asia Ventures Shanghai Ziyou Investment Management Zhongguancun Development Group Hetang Venture Capital Management (Beijing) BioTrack Capital SDIC Venture Capital China Ventures Fund Chang Development China Life Investment Management Qisheng Capital QingLan Fund Beijing Life Science Park Venture Capital Taiping Medical and Health Industry Equity Investment Fund	CNY700m	Series A
May 2024*	China Taiping Insurance Lilly Asia Ventures Shanghai Ziyou Investment Management Function Capital Baheal Pharmaceutical Shunxi Fund China Venture Capital Fund QingLan Fund Beijing Medical Fund	CNY200m Valuation: CNY4.5b	Series A
Total Funding		AUD191m

PYROTECH THERAPEUTICS

PYROTECH THERAPEUTICS

Related Content

Recent News about PYROTECH THERAPEUTICS